Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

How does technology impact nutrition management in older adults?

The use of technology in managing the nutrition of older adults.

October 19, 2023

Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio – Pharmaceutical Technology

Generalised myasthenia gravis is a rare condition – but UCB’s Rystiggo enters a competitive market. Source: Shutterstock / Giovanni Cancemi. Belgian biopharmaceutical company UCB has

June 27, 2023

Executive Board member Jens Ravens leaves the Company on April 30, 2024 – Biotech Investments

EQS-News: Epigenomics AG / Key word(s): Personnel Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 30.04.2024 / 15:00 CET/CEST The

May 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.